Vota-Hanbet B

Hanbet Co., Ltd. is a South Korean pharmaceutical company specializing in the research, development, and manufacturing of veterinary medicines. Founded in 1984, the company has established itself as a leader in the Korean animal health market, particularly through its innovative oncology portfolio. Its flagship product, Vota (pazopanib), is a multi-kinase inhibitor repurposed from human medicine to treat various solid tumors in companion animals, such as dogs. Hanbet's product range also includes a wide variety of anti-infectives, metabolic agents, and nutritional supplements for livestock and pets. The company maintains a strong focus on R&D to address unmet needs in veterinary clinical practice and is expanding its reach into global markets.